Trial Profile
A proof of concept trial of AQST-305 (octreotide sublingual formulation)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Nov 2018
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Aquestive Therapeutics
- 23 Nov 2018 New trial record
- 06 Nov 2018 According to an Aquestive Therapeutics media release, the company commenced this trial during the third quarter of 2018.